TY - JOUR
T1 - Consensus statement for diagnosis of subcortical small vessel disease
AU - Rosenberg, Gary A.
AU - Wallin, Anders
AU - Wardlaw, Joanna M.
AU - Markus, Hugh S.
AU - Montaner, Joan
AU - Wolfson, Leslie
AU - Iadecola, Costantino
AU - Zlokovic, Berislav V.
AU - Joutel, Anne
AU - Dichgans, Martin
AU - Duering, Marco
AU - Schmidt, Reinhold
AU - Korczyn, Amos D.
AU - Grinberg, Lea T.
AU - Chui, Helena C.
AU - Hachinski, Vladimir
N1 - Publisher Copyright:
© The Author(s) 2015.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Vascular cognitive impairment (VCI) is the diagnostic term used to describe a heterogeneous group of sporadic and hereditary diseases of the large and small blood vessels. Subcortical small vessel disease (SVD) leads to lacunar infarcts and progressive damage to the white matter. Patients with progressive damage to the white matter, referred to as Binswanger's disease (BD), constitute a spectrum from pure vascular disease to a mixture with neurodegenerative changes. Binswanger's disease patients are a relatively homogeneous subgroup with hypoxic hypoperfusion, lacunar infarcts, and inflammation that act synergistically to disrupt the blood-brain barrier (BBB) and break down myelin. Identification of this subgroup can be facilitated by multimodal disease markers obtained from clinical, cerebrospinal fluid, neuropsychological, and imaging studies. This consensus statement identifies a potential set of biomarkers based on underlying pathologic changes that could facilitate diagnosis and aid patient selection for future collaborative treatment trials.
AB - Vascular cognitive impairment (VCI) is the diagnostic term used to describe a heterogeneous group of sporadic and hereditary diseases of the large and small blood vessels. Subcortical small vessel disease (SVD) leads to lacunar infarcts and progressive damage to the white matter. Patients with progressive damage to the white matter, referred to as Binswanger's disease (BD), constitute a spectrum from pure vascular disease to a mixture with neurodegenerative changes. Binswanger's disease patients are a relatively homogeneous subgroup with hypoxic hypoperfusion, lacunar infarcts, and inflammation that act synergistically to disrupt the blood-brain barrier (BBB) and break down myelin. Identification of this subgroup can be facilitated by multimodal disease markers obtained from clinical, cerebrospinal fluid, neuropsychological, and imaging studies. This consensus statement identifies a potential set of biomarkers based on underlying pathologic changes that could facilitate diagnosis and aid patient selection for future collaborative treatment trials.
KW - Binswanger's disease
KW - blood-brain barrier permeability
KW - cerebrospinal fluid
KW - inflammation
KW - leukoaraiosis
UR - http://www.scopus.com/inward/record.url?scp=84951569839&partnerID=8YFLogxK
U2 - 10.1038/jcbfm.2015.172
DO - 10.1038/jcbfm.2015.172
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 26198175
AN - SCOPUS:84951569839
SN - 0271-678X
VL - 36
SP - 6
EP - 25
JO - Journal of Cerebral Blood Flow and Metabolism
JF - Journal of Cerebral Blood Flow and Metabolism
IS - 1
ER -